Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

6.640 -0.030 (-0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,830
Open 6.640
Bid (Size) 6.350 (1)
Ask (Size) 6.370 (1)
Prev. Close 6.670
Today's Range 6.640 - 6.670
52wk Range 3.730 - 11.62
Shares Outstanding 48,549,437
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Edges Higher; Indivior Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga

Performance

YTD
-4.18%
-4.18%
1 Month
+23.42%
+23.42%
3 Month
+27.69%
+27.69%
6 Month
+0.30%
+0.30%
1 Year
-42.51%
-42.51%

More News

Read More
Crude Oil Down 1%; Soligenix Shares Surge
Via Benzinga
Exposures Fossil Fuels
Why UniQure Stock Is Soaring
Via Benzinga
Recap: uniQure Q4 Earnings
Via Benzinga
MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing
Via InvestorPlace
Why Is uniQure (QURE) Stock Up 51% Today?
Via InvestorPlace
Dow Falls Over 50 Points; US Small Business Optimism Surges In June
Via Benzinga
Topics Stocks
Exposures US Equities
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Via Investor's Business Daily
Exposures Product Safety
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
From uniQure Inc.
Via GlobeNewswire
3 Micro-Cap Stocks That Could Be Moonshots
Via InvestorPlace
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.